Hydroxyurea Clinical Trials

6 actively recruiting trials across 5 locations

Also known as: Droxia, Hydrea, Hydroxycarbamide, ITF2357, Litalir, Onco-Carbide, Oncocarbide, Oxeron, SQ 1089, SQ-1089, Syrea, WR 83799, hydroxycarbamide

Filter by location:

Pittsburgh, Pennsylvania2 trials

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

UPMC Presbyterian

Phase 1/2

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

UPMC Children's Hospital of Pittsburgh

Phase 2

Birmingham, Alabama1 trial

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

University of Alabama at Birmingham

Phase 3

Tampa, Florida1 trial

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Moffitt Cancer Center

Phase 2

Chicago, Illinois1 trial

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

The University of Chicago

Phase 1

Buffalo, New York1 trial

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.